TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats
- 13 July 2011
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 339 (1), 228-237
- https://doi.org/10.1124/jpet.111.183772
Abstract
G protein-coupled receptor 40/free fatty acid receptor 1 (GPR40/FFA1) is highly expressed in pancreatic β cells and mediates free fatty acid-induced insulin secretion. This study examined the pharmacological effects and potential for avoidance of lipotoxicity of [(3S)-6-({2′,6′-dimethyl-4′-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate) (TAK-875), a novel, orally available, selective GPR40 agonist. Insulinoma cell lines and primary rat islets were used to assess the effects of TAK-875 in vitro. The in vivo effects of TAK-875 on postprandial hyperglycemia, fasting hyperglycemia, and normoglycemia were examined in type 2 diabetic and normal rats. In rat insulinoma INS-1 833/15 cells, TAK-875 increased intracellular inositol monophosphate and calcium concentration, consistent with activation of the Gqα signaling pathway. The insulinotropic action of TAK-875 (10 μM) in INS-1 833/15 and primary rat islets was glucose-dependent. Prolonged exposure of cytokine-sensitive INS-1 832/13 to TAK-875 for 72 h at pharmacologically active concentrations did not alter glucose-stimulated insulin secretion, insulin content, or caspase 3/7 activity, whereas prolonged exposure to palmitic or oleic acid impaired β cell function and survival. In an oral glucose tolerance test in type 2 diabetic N-STZ-1.5 rats, TAK-875 (1–10 mg/kg p.o.) showed a clear improvement in glucose tolerance and augmented insulin secretion. In addition, TAK-875 (10 mg/kg, p.o.) significantly augmented plasma insulin levels and reduced fasting hyperglycemia in male Zucker diabetic fatty rats, whereas in fasted normal Sprague-Dawley rats, TAK-875 neither enhanced insulin secretion nor caused hypoglycemia even at 30 mg/kg. TAK-875 enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia with a low risk of hypoglycemia and no evidence of β cell toxicity.Keywords
This publication has 33 references indexed in Scilit:
- Deletion of GPR40 Impairs Glucose-Induced Insulin Secretion In Vivo in Mice Without Affecting Intracellular Fuel Metabolism in IsletsDiabetes, 2009
- Overexpression of GPR40 in Pancreatic β-Cells Augments Glucose-Stimulated Insulin Secretion and Improves Glucose Tolerance in Normal and Diabetic MiceDiabetes, 2009
- Lack of FFAR1/GPR40 Does Not Protect Mice From High-Fat Diet–Induced Metabolic DiseaseDiabetes, 2008
- The Fatty Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo After High-Fat FeedingDiabetes, 2008
- Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in MiceDiabetes, 2008
- GPR40 Is Necessary but Not Sufficient for Fatty Acid Stimulation of Insulin Secretion In VivoDiabetes, 2007
- GPR40 is expressed in glucagon producing cells and affects glucagon secretionBiochemical and Biophysical Research Communications, 2007
- Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small moleculesBritish Journal of Pharmacology, 2006
- Oleic acid interacts with GPR40 to induce Ca2+signaling in rat islet β-cells: mediation by PLC and L-type Ca2+channel and link to insulin releaseAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Role of GPR40 in fatty acid action on the β cell line INS-1EBiochemical and Biophysical Research Communications, 2005